Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.

Abstract: The present disclosure discloses an optical imaging lens group. The optical imaging lens group comprises, sequentially along an optical axis from an object side to an image side, a first lens, a second lens, a third lens, a fourth lens, a fifth lens, a sixth lens, a seventh lens and an eighth lens, wherein the first lens, the second lens, the third lens, the fourth lens, the fifth lens, the sixth lens, the seventh lens and the eighth lens have refractive powers. At least one lens in the first lens to the eighth lens has a non-rotationally symmetric aspheric surface; a total effective focal length fy of the optical imaging lens group in a Y-axis direction and a total effective focal length fx of the optical imaging lens group in an X-axis direction satisfy: fy/fx<0.8; and an f-number Fnoy of the optical imaging lens group in the Y-axis direction satisfies: Fnoy<2.9.

Abstract: The present invention belongs to the technical field of turbine cooling of aero-engine and gas turbine, and relates to the honeycomb-like helically cavity cooling structure of turbine blade. The honeycomb-like helically cavity cooling structure of turbine blade includes hollow turbine blade, honeycomb-like helically cavity and pin fins. Some cooling channels are arranged inside the hollow the hollow turbine blade, the cooling gas flows through the tunnels and cools the blade. Multi-arrays of honeycomb-like helically cavity are arranged in the blade wall, for cooling gas to enter and convective cooling. A cylindrical pin fin is arranged in the center of the honeycomb-like helically cavity. In each unit, the inlet hole and film hole are located on both sides of the blade wall, and the center lines of them are parallel in the same vertical plane.

Abstract: The disclosure provides an optical imaging lens group, which sequentially includes from an object side to an image side along an optical axis: a first lens with a negative refractive power; a second lens with a refractive power; a third lens with a refractive power, an image-side surface thereof is a concave surface; a fourth lens with a negative refractive power; a fifth lens with a refractive power; and a sixth lens with a refractive power. Semi-FOV is a half of a maximum field of view of the optical imaging lens group, and Semi-FOV satisfies 45°<Semi-FOV<55°. A curvature radius R1 of an object-side surface of the first lens, a curvature radius R2 of an image-side surface of the first lens, a curvature radius R3 of an object-side surface of the second lens and a curvature radius R4 of an image-side surface of the second lens satisfy 0.5<(R1+R2)/(R3?R4)<1.5.

Abstract: The present disclosure discloses an optical imaging lens assembly including, sequentially from an object side to an image side along an optical axis, a first lens having negative refractive power; a second lens having refractive power; a third lens; a fourth lens having refractive power, a convex image-side surface and a concave image-side surface; a fifth lens having refractive power and a concave object-side surface; a sixth lens; and a seventh lens. Half of a diagonal length ImgH of an effective pixel area on an imaging plane of the optical imaging lens assembly satisfies: ImgH?5.20 mm.

Abstract: The disclosure provides an optical imaging system, sequentially including a first lens, a second lens, a third lens, a fourth lens, a fifth lens, a sixth lens, a seventh lens and an eighth lens from an object side to an image side along an optical axis, wherein an image-side surface of the seventh lens is a concave surface; the optical imaging system meets the following conditional expressions: TTL/ImgH<1.3, f/EPD<1.8, ImgH>6 mm and 0<R15/f8<0.8, wherein TTL is a distance from an object-side surface of the first lens to an imaging surface of the optical imaging system on the optical axis; ImgH is a half of diagonal length of an effective pixel region on the imaging surface; f is a total effective focal length of the optical imaging system; EPD is an entrance pupil diameter of the optical imaging system.

Abstract: The present disclosure discloses an optical imaging lens assembly, sequentially from an object side to an image side along an optical axis, including: a first lens having refractive power, an object-side surface thereof is concave, and an image-side surface thereof is convex; a second lens having refractive power; a third lens having refractive power; a fourth lens having refractive power; a fifth lens having negative refractive power, and an object-side surface thereof is concave; a sixth lens having positive refractive power; and a seventh lens having refractive power. A total effective focal length f of the optical imaging lens assembly and an effective focal length f3 of the third lens may satisfy f3/f>1.49.

Abstract: The present disclosure discloses an optical imaging system, sequentially from an object side to an image side of the optical imaging system along an optical axis, including: a first lens having refractive power; a second lens having negative refractive power; a third lens having refractive power; a fourth lens having positive refractive power; a fifth lens having refractive power; a sixth lens having refractive power; and a seventh lens having refractive power, a concave object-side surface, and a concave image-side surface. Half of a diagonal length ImgH of an effective pixel area on an imaging plane of the optical imaging system may satisfy ImgH>6.0 mm. A total effective focal length f of the optical imaging system and an entrance pupil diameter EPD of the optical imaging system may satisfy f/EPD<1.9.

Abstract: An optical imaging system includes an optical lens group including, sequentially along an optical axis from an object side to an image side, a first lens, a second lens, a third lens, and a fourth lens; a lens barrel, the optical lens group is accommodated in the lens barrel; and a plurality of spacers including at least two spacers disposed between the third lens and the fourth lens; the diameter D of the lens barrel at an end towards the object side and a maximum effective radius DT11 of an object-side surface of the first lens satisfy 2×DT11/D?0.5.

Abstract: The disclosure provided herein relates generally to mesenchymal-like stem cells “hES-T-MiSC” or “T-MSC” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hES-T-MSC or T-MSC, T-MSC derived cell and cell lineages “T-MSC-DL” are also described. Disclosed also herein are solutions and pharmaceutical compositions comprising the T-MSC and/or T-MSC-DL, methods of making the T-MSC and T-MSC-DL, and methods of using the T-MSC and T-MSC-DL for treatment and prevention of diseases, specifically, T-MSC and T-MSC-DL are used as immunosuppressive agents to treat multiple sclerosis and autoimmune diseases.

Abstract: The present disclosure discloses an optical imaging lens group including, sequentially from an object side to an image side along an optical axis, a first lens having positive refractive power with a convex object-side surface; a second lens having refractive power; a third lens having refractive power; a fourth lens having refractive power; a fifth lens having refractive power; and a sixth lens having negative refractive power with a concave object-side surface and a convex image-side surface. A total effective focal length f of the optical imaging lens group, an entrance pupil diameter EPD of the optical imaging lens group and half of a maximal field-of-view Semi-FOV of the optical imaging lens group satisfy: f/EPD<2, and f*tan(Semi-FOV)>4.5 mm.

Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.

Abstract: The present invention relates to methods of generating and expanding pitman embryonic stem cell derived mesenchymal-like stem/stromal cells. These hES-MSCs are characterized at least in part by the low level of expression of IL-6. These cells are useful for the prevention and treatment of T cell related autoimmune disease, especially multiple sclerosis, as well as for delivering agents across the bland-brain barrier and the blood-spinal cord barrier. Also provided is a method of selecting clinical grade hES-MSC and a method of modifying MSC to produced a MSC with specific biomarker profile. The modified MSC are useful for treatment of various diseases.

Abstract: This document provides methods and materials for treating polycystic diseases such as polycystic kidney disease. For example, methods for using a TRPV2 agonist (e.g., probenecid) and optionally a vasopressin receptor antagonist (e.g., tolvaptan) to treat a mammal having polycystic kidney disease (e.g., autosomal dominant polycystic kidney disease) are provided.

Abstract: The disclosure provided herein relates generally to mesenchymal-like stem cells “hES-T-MiSC” or “T-MSC” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblast in hES-T-MSC or T-MSC, T-MSC derived cells and cell lineages “T-MSC-DL” are also described. Disclosed also herein are solutions and pharmaceutical compositions comprising the T-MSC and/or T-MSC-DL, methods of making the T-MSC and T-MSC-DL, and methods of using the T-MSC and T-MSC-DL for treatment and prevention of diseases, specifically. T-MSC and T-MSC-DL are used as immunosuppressive agents to treat multiple sclerosis and autoimmune diseases.

Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.

Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Exemplary compounds of the invention have the structure of Formula 1. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.

Abstract: The present invention relates to methods of generating and expanding hitman embryonic stem cell derived mesenchymal-like stem/stromal cells. These hES-MSCs are characterized at least in part by the low level of expression of IL-6. These cells are useful for the prevention and treatment of T cell related autoimmune disease, especially multiple sclerosis, as well as for delivering agents across the blood-brain barrier and the blood-spinal cord barrier. Also provided is a method of selecting clinical grade hES-MSC and a method of modifying MSC to produced a MSC with specific biomarker profile. The modified MSC are useful for treatment of various diseases.

Abstract: A water-cooled column (4) used in a circulating fluidized bed boiler furnace is disclosed, wherein the water-cooled column is formed by connecting membrane water-cooled walls (41). The water-cooled column (4) includes a lower section (A), an upper section and a transition section. The lower section (A) is a single column and is provided with inner secondary air ports (400) on a side wall thereof. The upper section includes a plurality of sub-columns (B, C). The membrane water-cooled walls at the lower section (A) extend to the upper section through the transition section. Each of the sub-columns (B, C) is formed by connecting extension portions extending upward from respective membrane water-cooled walls (41) in the membrane water-cooled walls (41), which are connected to form the lower section (A), and the plurality of sub-columns (B, C) are separated from each other.

Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.